Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 26, 2026OncogeneOpen Access

Targeting VPS4 elicits STING-driven anti-tumor immunity to suppress rhabdomyosarcoma growth

View Full Paper
Ask AI
Bookmark
Share

Authors

RZRay ZhangLCLonggui ChenXLXinwen Liang

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates tumor growth suppression in rhabdomyosarcoma, suggesting a new therapeutic strategy.

Key Points

  • This research investigates how inhibiting VPS4 affects tumor growth and boosts anti-tumor immunity in rhabdomyosarcoma.
  • Used pharmacological and genetic approaches to inhibit VPS4 in murine rhabdomyosarcoma models.
  • Analyzed immune signaling pathways activated by VPS4 inhibition, focusing on the cGAS-STING-TBK1-IRF3 axis.
  • Monitored tumor growth rates and immune cell infiltration following VPS4 inhibition.
  • VPS4 inhibition led to significant tumor growth suppression in RMS (p<0.05).
  • Cytokine signaling was markedly increased, with an activation of the cGAS-STING pathway (p<0.01).
  • Loss of STING reduced immune cell infiltration by natural killer and dendritic cells, impairing anti-tumor effects (p<0.05).

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/69edacbd4a46254e215b4723https://doi.org/10.1038/s41388-026-03800-1
View Full Paper
Ask AI
Bookmark
Share